Business
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income o...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United StatesFiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 millionUS commercial launch of GRAFAPEX™ executed in February 2025, following swiftly on the FDA's approval in January 2025, with initial indicators supporting Medexus's confidence in the product's potentialManagement to host conference call at 8:00 AM Eastern time on Thursday, June 26, 2025Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2025 (the company's fiscal Q4 2025 and fiscal year 2025). All dollar amounts in this press release are in United States dollars unless specified otherwise.Key business updateMedexus executed a commercial launch of GRAFAPEX™ (treosulfan) for Injection with product commercially available in the United States in February 2025. The launch, which was originally expected to occur by April 2025, followed swiftly on the FDA's approval of the product in January 2025, allowing Medexus to begin generating product-level revenue in fiscal Q4 2025. Based on internal estimates and research, Medexus continues to expect that annual product-level revenue from GRAFAPEX will exceed US$100 million within five years after commercial launch.Medexus has seen a positive market response to GRAFAPEX to date, with progress consistent with Company expectations:Four large commercial payers, together covering an estimated 34 million patient lives, and 12 individual healthcare institutions, representing 7% of the 180 transplant centers in the United States, have made positive formulary inclusion determinations, a promising indicator of the product's commercial potential. An additional 15 commercial payers have added GRAFAPEX on their \"prior authorization\" lists.Wholesaler data shows that 34 of the 180 transplant centers have already ordered GRAFAPEX for procedures in their institutions.Medexus achieved $0.6 million of product-level revenue from GRAFAPEX in fiscal Q4 2025, relative to $2.7 mi...